IOVA Company Financial Information

Symbol Info
Iovance Biotherapeutics Inc. (IOVA)
Listed Symbol	IOVA
Name	Iovance Biotherapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share	$-
Latest Fiscal Date	2018-12-31
Latest Fiscal Revenue	$-
Latest Fiscal EPS	$-1.27
Price Info
21 Day Moving Average	$23.4033
21 Day EMA	$22.530580
50 Day Moving Average	$22.8324
50 Day EMA	$21.700580
200 Day EMA	$16.088780
200 Day Moving Average	13.615300
52 Week High	$26.59
52 Week Low	$7.26
52 Week Change	$32.176700
Alpha	0.025439
Beta	1.9323
Standard Deviation	0.216365
R2	0.096019
Periods	60
Share Information
10 Day Average Volume	1,331,201
20 Day Average Volume	1,274,225
30 Day Average Volume	1,212,685
50 Day Average Volume	1,602,770
Outstanding Shares	123,830,506
Float Shares	102,808,844
Percent Float	83.02%
Short Interest	-
Short Percent Float	-
Short Interest Ratio	-
Short Date
Holders
Institutions	303
Institute Holdings Date	2019-07-31
Institute Bought Previous 3 Months	6,999,474
Institute Holdings Percent	-
Institute Sold Previous 3 Months	11,263,644
Insider Holdings Date
Insider Bought Previous 3 Months	-
Insider Holdings Percent	-
Insider Sold Previous 3 Months	-
Insiders Shares Owned	21,021,662
Price Change
7 Day Price Change	$-1.289999
7 Day Percent Change	-5.80%
21 Day Price Change	$-3.9499989
21 Day Percent Change	-15.86%
30 Day Price Change	$-3.8899994
30 Day Percent Change	-15.66%
Month To Date Price Change	$-3.64
Month To Date Percent	-14.80%
90 Day Price Change	$5.670001
90 Day Percent Change	37.11%
Quarter To Date	$-3.57
Quarter To Date Percent	-14.56%
180 Day Price Change	$10.620001
180 Day Percent Change	102.81%
200 Day Price Change	$12.520000
200 Day Percent Change	148.52%
Year To Date	$12.100000
Year To Date Percent	136.72%
Profile
Description	Iovance Biotherapeutics Inc operates in the healthcare sector based in the United States. It is a pharmaceutical manufacturer attending to serious diseases such as cancer. The Company's lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The TIL therapy involves growing a patient's special culture conditions outside the patient's body, or ex vivo, and then infusing the T cells back into the patient.
Details
Issue Type	CS
Market Cap	$2,594,249,101
Sec Type	EQS
Auditor	Marcum LLP
Total Shares Outstanding	123,830,506
CEO	Maria Fardis
Employees	88
Last Audit	UQ
Classification
CIK	0001425205
Industry	Biotechnology
Sector	Healthcare
NAICS	Medicinal and Botanical Manufacturing(325411)
Info
Address	999 Skyway Road Suite 150 San Carlos, CA 94070
Website	https://www.iovance.com
Facisimile
Telephone	+1 650 260-7120
Email	sarah@sternir.com
Key Ratios
Profitability
EBIT Margin	-
EBITDA Margin	-
Pre-Tax Profit Margin	-
Profit Margin Cont	-
Gross Margin	-
Profit Margin TOT	-
Income Statements
Revenue	$-
Revenue Per Share	$-
Revenue 3 Years	$-
Revenue 5 Years	$-
Valuation Measures
PE Ratio	-
Enterprise Value	$2,087,036,730
Price To Sales	-
Price To Free Cash	-19.8
PE High Last 5 Years	-
Price To Book	6.2
Price To Cash Flow	-
PE Low Last 5 Years	-
Price To Tangible Book	6.2
Financial Strength
Total Debt To Equity	0.0
Int Coverage	-
Current Ratio	12.1
Leverage Ratio	1.1
Quick Ratio	11.9
Long Term Debt To Capital	0.01
Assets
Receivables Turnover	-
Invoice Turnover	-
Assets Turnover	-
Management Effectiveness
Return Assets	-41.88
Return On Equity	-45.18
Return On Capital	-43.6
Dividends
Dividend 3 Years	$-
Dividend 5 Years	$-
Ex Dividend Date
Dividend Rate	$-
Dividend Yield	-
Payment Type